More companies develop tests for the breast cancer gene
This article was originally published in Clinica
Bayer Diagnostics and Oncogene Science Diagnostics plan to submit two versions of a serum test for the prognostic breast cancer marker HER-2/neu for US clearance later this year. The announcement comes after trials of the test showed a strong correlation between high levels of the marker and aggressive, metastatic breast cancer.
You may also be interested in...
Under EU rules, once a medicinal product has been placed on the market in a country of the EEA – the EU plus Iceland, Liechtenstein and Norway
Trademarks are registered and published for opposition with the US Patent and Trademark Office and are published weekly in the agency's Official Gazette.
The national regulator is to undergo a review in 2021 as the UK begins life as a former EU member, presenting opportunities to be seized.